Jo Lydie W Lambert

Jo Lydie W Lambert
Ghent University | UGhent · Department of Dermatology

MD, PhD

About

302
Publications
42,173
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
7,531
Citations
Citations since 2016
101 Research Items
4502 Citations
20162017201820192020202120220200400600800
20162017201820192020202120220200400600800
20162017201820192020202120220200400600800
20162017201820192020202120220200400600800
Introduction
Jo Lambert is Senior Full Professor in Dermatology and Venerology and Academic Head of the department of Dermatology at Ghent University Hospital in Belgium. Professor Lambert previously studied at the Dermatology Department at Boston University and the Centre for Electron Microscopy at Leiden University. Professor Lambert is a board member of several national and international psoriasis (and policy) expert committees and is presently the President of the Royal Society of Dermatology and Venereology and member of the Royal Academy of Medicine, Belgium. She is the Past President of the Skin Inflammation and Psoriasis International Network (SPIN). Professor Lambert is passionate about ensuring patients suffering with chronic skin disease receive the best care and support. She runs an academic expert clinic for psoriasis (PsoPlus) and other skin immune diseases. Special interest currently goes to precision medicine, and value-based healthcare in these diseases. Professor Lambert has published more than 170 articles in peer-reviewed journals and made contributions to several textbooks.
Additional affiliations
January 1997 - March 1997
Leiden University
Position
  • PhD Student
Description
  • Immuno electron microscopy study on melanosome transport in Griscelli syndrome patients in collaboration with Dr M Mommaas and H Koerten
June 1994 - present
Ghent University
Position
  • Head of Department
June 1994 - May 2017
Ghent University
Position
  • Professor

Publications

Publications (302)
Article
Full-text available
Importance: There is a need to define which outcomes matter to patients with psoriasis to deliver value for the patient when managing their condition. Objectives: To generate a comprehensive overview of all outcomes relevant in the management of psoriasis as defined by patients. Evidence review: A systematic review was performed by searching 3...
Article
Full-text available
Therapeutic drug monitoring (TDM) of biologics-encompassing the measurement of (trough) concentrations and anti-drug antibodies-is emerging as a valuable tool for clinical decision making. While this strategy needs further validation, attention on its implementation into the clinic is warranted. Rapid testing and easy sampling are key to its implem...
Article
Full-text available
Background: Despite the favorable efficacy profile of secukinumab, clinicians encounter varying clinical responses amongst patients potentially associated with under- and overexposure. As biologics are expensive, rational use is crucial and evident. Therapeutic drug monitoring could guide clinicians in their decision-making regarding treatment mod...
Article
Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory bowel disease (IBD). However, challenges remain and are hindering the widespread implementation of TDM in clinical practice. These barriers include identification of th...
Preprint
Background COVID-19 vaccination is efficacious at protecting against severe COVID-19 outcomes in the general population. However, vaccine hesitancy (unwillingness for vaccination despite available vaccination services) threatens public health. Individuals taking immunosuppression for psoriasis have been prioritised for COVID-19 vaccination, however...
Article
Background Immunomodulators (IMM) and Targeted Immune-Modulating Therapies (TIMT) such as anti-TNF, anti-interleukins and Janus Kinase inhibitors, for treatment of Immune Mediated Inflammatory diseases (IMID) could theoretically interfere with the cytokine storm and humoral immune response against COVID19 infection and vaccination. We investigate s...
Article
Full-text available
IntroductionApremilast is approved for the treatment of psoriasis and psoriatic arthritis. However, data on the efficacy and safety of apremilast in clinical practice are limited. We assessed the real-world use and effectiveness of apremilast in patients with moderate to severe plaque psoriasis visiting dermatologist practices in Belgium, from the...
Article
Full-text available
Background Psoriasis is a chronic inflammatory skin disease associated with numerous comorbidities. Psoriasis has been linked to an increased risk of metabolic syndrome and atherosclerotic arterial disease. Inflammatory conditions are known to increase the risk of venous thromboembolism (VTE), a frequent cause of morbidity and mortality. However, t...
Article
Introduction La rapidité d’amélioration des symptômes du psoriasis est l’une des attentes les plus appréciées par les patients et constitue un objectif important du traitement. Nous évaluons ici l’efficacité et l’impact sur la qualité de vie du traitement par bimékizumab versus des comparateurs au cours des 16 premières semaines de traitement chez...
Article
Full-text available
Objectives Studies on variability drivers of treatment costs in hospitals can provide the necessary information for policymakers and healthcare providers seeking to redesign reimbursement schemes and improve the outcomes-over-cost ratio, respectively. This systematic literature review, focusing on the hospital perspective, provides an overview of s...
Article
Full-text available
Objective: To assess the feasibility of the future implementation of a recently published Belgian treat-to-target scoring in daily practice, we investigated to what extent Belgian dermatologists use metrics and take comorbidities into account in the follow-up of psoriasis patients. Methods: Belgian dermatologists were addressed to fill out an on...
Article
Full-text available
Background Physician-reported clinical outcome and quality of life (QoL) measures are currently used to assess outcomes and direct treatment of plaque psoriasis. However, people with psoriasis may have different criteria for judging treatment success. Objectives To build a unified consensus on the definition of ‘freedom from disease’ from a Europe...
Article
Full-text available
Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics. A substantial part of patients on tumor necrosis factor (TNF)-alfa inhibitors and ustekinumab could succe...
Article
Indirect excess morbidity in the COVID‐19 pandemic may arise from public health risk‐mitigation efforts such as stay‐at‐home orders and re‐purposing of healthcare services1. Increased mental health disorders and shortfalls in the care of long‐term conditions are described.
Article
Full-text available
Large-scale vaccination strategies are currently being deployed against severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2). Whether systemic medication for skin diseases affects the efficacy of vaccination and whether temporary interruption or extension of the dosing interval is necessary is under debate. Most immunomodulating/immunosuppr...
Article
Background It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of time. Targeted Immune-Modulating Therapies (TIMT) such as anti-TNF, anti-interleukins and Janus Kinase inhibitors (JAKi) for treatment of Immune Mediated Inflammatory diseases (IMID) could th...
Article
Full-text available
IntroductionTargeted biological therapies for psoriasis have resulted in significant benefits, with therapeutic goals such as clear or almost clear skin accompanied by improvements in health-related quality of life (HRQoL). The objective of this study was to compare the effects of 52 weeks of treatment with brodalumab or ustekinumab on HRQoL in pat...
Preprint
Full-text available
Background Indirect excess morbidity has emerged as a major concern in the COVID-19 pandemic. People with psoriasis may be particularly vulnerable to this because of prevalent anxiety and depression, multimorbidity and therapeutic use of immunosuppression. Objective Characterise the factors associated with worsening psoriasis in the COVID-19 pandem...
Article
Full-text available
Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is characterized by the frequent development of blisters and erosions on the skin and mucous membranes. The rarity of the disease and the heterogeneity of the underlying mutations renders therapy developments challenging. However, the high number of short in-frame...
Article
Full-text available
The biologic era has greatly improved the treatment of Crohn's disease and ulcerative colitis. Biologics can however induce a wide variety of skin eruptions, especially those targeting the TNF-α and Th17 pathway. These include infusion reactions, eczema, psoriasis, lupus, alopecia areata, vitiligo, lichenoid reactions, granulomatous disorders, vasc...
Article
Full-text available
Objectives Registry data suggest that people with immune‐mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID‐19 outcomes compared to patients receiving no systemic treatments. We used international patient survey data to explore the hypothesis that greater risk‐mitigating behaviour in those receivin...
Article
Full-text available
Background: Psoriasis is a complex disease associated with multiple comorbidities, including metabolic syndrome and leaky gut syndrome. Dietary lifestyle interventions have been reported to affect the disease in terms of lesional severity. It remains unclear how diets affect these comorbidities and the general health in psoriasis patients. Modifie...
Preprint
BACKGROUND Psoriasis is a complex disease associated with multiple comorbidities, including metabolic syndrome and leaky gut syndrome. Dietary lifestyle interventions have been reported to affect the disease in terms of lesional severity. It remains unclear how diets affect these comorbidities and the general health in psoriasis patients. Modified...
Article
Full-text available
Background Itch is a common symptom in the general population. Affected individuals often do not seek medical consultation and rely on internet searches to obtain information regarding their itch. Objectives The aim of this study was to attain insights into common concerns of the general population regarding itch can by analyzing itch‐related inte...
Article
Introduction Le tildrakizumab (TIL) est un anticorps monoclonal de haute affinité ciblant spécifiquement l’interleukine (IL)-23p19 approuvé pour le traitement du psoriasis en plaques modéré à sévère. L’objectif était d’évaluer les taux de tumeurs malignes sur 5 ans des deux essais de phase 3 : reSURFACE 1/2 (NCT01722331/NCT01729754). Matériel et m...
Article
The 2019 Interactive Derma Academy (IDeA) meeting was held in Lisbon, Portugal, 10–12 May, bringing together leading dermatology experts from across Europe, the Middle East and Asia. Over three days, the latest developments and challenges in relation to the pathophysiology, diagnosis, evaluation and management of dermatological conditions were pres...
Preprint
Full-text available
Objectives Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receivin...
Article
Background: Therapeutic drug monitoring (TDM) may lead to more rational use of biologics. Still, TDM is largely underexplored in psoriasis. Little is known about the dosing behavior of biologics by dermatologists, and their attitude toward TDM. Objective: Exploration of the awareness and need for the concept of TDM in psoriasis amongst (inter)na...
Article
Full-text available
Importance Demonstrating the value of therapies from a patient’s perspective is increasingly important for patient-centered care. Objective To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life (HRQL), and mental health among patients with moderate to severe p...
Article
Full-text available
The autoimmune basis of segmental vitiligo (SV) has only recently been recognized. Systemic autoimmune diseases are less frequently associated compared to non-segmental vitiligo (NSV), but localized skin disorders – in particular linear morphea – have been repeatedly observed in patients with SV. The inflammatory response is documented on a clinica...
Article
Background The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited. Objective Our aim was to characterize the course of COVID-19 in patients with psoriasis and identify factors associated with hospitalization....
Article
Full-text available
Background Impressive progress in new therapeutic options has been made for psoriasis. Treatments include topical steroids, phototherapy, conventional, synthetic disease‐modifying drugs and an expanding list of biologics. Objective The primary objective of this work was to collect evidence for the creation of practice guidelines for systemic treat...
Article
Full-text available
Background Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co‐occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant d...
Article
It is largely unknown how reliable patients with psoriasis and eczema can estimate their involved body surface area (BSA). Nonetheless, this calculation is important for the development of patient‐reported outcome measures (PROMs). The current standards remain the rule of hands (= 1 hand palm surface area equals 1% BSA) and the rule of nines (= cha...
Article
We read with great interest the multicenter and retrospective study of Fougerosse et al1 that investigated real‐life effectiveness and tolerance of guselkumab at week 16 in the treatment of cutaneous psoriasis. In the same manner, we conducted the first multicenter study in Belgium aiming to investigate real‐life effectiveness and tolerance of guse...
Article
Full-text available
Background Risankizumab is a humanized IgG monoclonal antibody that selectively inhibits interleukin‐23 through binding the p19 subunit. In Phase 3 trials, risankizumab demonstrated superior efficacy compared with adalimumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis. Here, we evaluated the impact of baseline characteristi...
Article
Objectives: Psoriasis is a chronic skin disease requiring a multidimensional approach, given its varying appearance, presence of comorbidities and complex treatment regimens. Psoriasis care is however often performed fragmented and, in case of flares, reactive with little integrated information on and for the patient. Literature suggests a multilev...
Article
Background: Psoriasis and atopic dermatitis are chronic skin diseases that greatly affect the quality of life. Both diseases can be triggered or exacerbated by stress. Objective: We aimed to differentiate personality traits between patients with chronic skin conditions and people treated for stress in a pilot study. Methods: Patients participa...
Article
Importance Few studies have compared the use of methotrexate and biologics, the most commonly used systemic medications for treatment of moderate to severe psoriasis in children. Objective To assess the real-world, 6-month reduction in psoriasis severity and long-term drug survival (rate and duration of adherence to a specific drug) of methotrexat...
Article
银屑病是一种慢性炎症性皮肤病,会导致皮肤发红、发痒和鳞斑。它影响大约 2%‐3% 的西方人口。在中度至重度病例中,患者会使用乌司奴单抗等生物药物治疗。 尽管已证明这些药物可改善患者的症状,但仍有一些个体对治疗无反应,意味着他们看不到任何改善,或者随着时间的流逝失去反应,意味着改善程度有所降低。 失去反应的原因之一是患者血液中的药物浓度过低。因此,测定药物浓度以了解患者体内药物的状况或许是个有吸引力的研究方向。但是,仅当药物浓度与皮肤疾病的状况有关时,测定药物浓度才有用。 这项在比利时进行的研究旨在确定乌司奴单抗药物的浓度是否与临床反应(症状是否有所改善)相关。因此,在注射乌司奴单抗后四周,对 49 例中重度银屑病患者的血液中乌司奴浓度进行了测定。 作者发现,乌司奴单抗浓度较高的患者比浓度低的...
Article
Psoriasis is a chronic inflammatory skin disease causing red, itchy and scaly patches of skin. It affects about 2‐3% of the Western population. In moderate‐to‐severe cases, patients are treated with drugs called biologicals, including ustekinumab. Although these drugs have been shown to improve patients’ symptoms, there are still individuals that d...
Article
Introduction Le concept de prurigo étant très vague et donc très variable selon les pays, la task force de l’EADV sur le prurit a organisé des réunions de consensus pour obtenir une définition, une classification et une terminologie sur le prurigo chronique qui soient communes et fassent donc autorité. Matériel et méthodes Des discussions sur des...
Article
Full-text available
Objective: Treat-to-target (T2T) is an algorithm to reach a predefined outcome. Here we define a T2T outcome for moderate-to-severe psoriasis vulgaris. Methods: Briefly, the study included a literature review; discussions with key opinion leaders; recruitment of additional dermatologists with experience in managing moderate-to-severe psoriasis;...
Article
Full-text available
The impressive potential of biologics has been demonstrated in psoriasis, hidradenitis suppurativa, and urticaria. Numerous biologicals are entering the field for a restricted number of skin disorders. Off-label use of biologics in other recalcitrant skin diseases has increased. Mounting data point to the potential of already existing biologics act...
Article
Full-text available
Background: Genetic predictors for treatment response could optimize allocation of biological treatment in patients with psoriasis. There is minimal knowledge about pharmacogenetics of anti-IL17 agents. Objectives: To assess whether genetic variants in the protein-coding region or untranslated regions of the IL17A gene are associated with respon...
Article
Psoriasis ist eine chronisch‐entzündliche Hautkrankheit. Patientenschulungen könnten eine Möglichkeit sein, die Adhärenz und die Bewältigungsstrategien (Coping) zu verbessern. Das Ziel dieser systematischen Übersichtsarbeit ist es, Studien zu ermitteln, in denen Schulungsinterventionen für Psoriasis‐Patienten evaluiert werden. Die Übersichtsarbeit...
Article
Full-text available
Introduction: Biologic therapy has revolutionized the treatment of immune mediated inflammatory diseases (IMID), such as inflammatory bowel disease (IBD), rheumatoid and psoriatic arthritis, ankylosing spondylitis and psoriasis. Nevertheless, some patients exhibit primary nonresponse (PNR) or secondary loss of response (SLR) to biologics. Areas cov...
Article
Background The accurate determination of the dosage of topical treatments is important given its repercussions on patient adherence and therapeutic efficacy. Up till now, the fingertip unit calculated by the rule of hands is considered the gold standard, although its use is associated with several drawbacks. Objective To compare different methods...
Article
Full-text available
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine. Methods: To investigate the role of ustekinumab serum concentrations, anti-ustekinumab antibodies [AUA] and HLA-Cw6 status as...
Article
Full-text available
Background Cost‐effective use of biologicals is becoming increasingly important. Monitoring drug concentrations has emerged as a valuable tool to guide clinical decision‐making as drug concentrations have been linked to clinical outcomes. The presence of a concentration‐response relationship for ustekinumab at trough is uncertain due to the contrad...
Article
Full-text available
Background: Teledermatology, the application of telemedicine in the field of dermatology, can be a valuable tool to improve the efficiency of care in general practice. Objectives: In this pilot study, we implemented a teledermatology programme in Belgian context to assess the effect on referral rate and to evaluate the acceptability of teledermatol...